Cormorant Asset Management, LP Moon Lake Immunotherapeutics Transaction History
Cormorant Asset Management, LP
- $1.27 Billion
- Q4 2024
A detailed history of Cormorant Asset Management, LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,494,151 shares of MLTX stock, worth $371 Million. This represents 35.64% of its overall portfolio holdings.
Number of Shares
8,494,151
Previous 8,494,151
-0.0%
Holding current value
$371 Million
Previous $428 Million
5.39%
% of portfolio
35.64%
Previous 30.01%
Shares
4 transactions
Others Institutions Holding MLTX
# of Institutions
136Shares Held
60.6MCall Options Held
118KPut Options Held
89.7K-
Bvf Inc San Francisco, CA19.8MShares$862 Million39.28% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$146 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$121 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$95.4 Million0.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY1.77MShares$77.3 Million3.59% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.61B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...